Page tree
Skip to end of metadata
Go to start of metadata

Maraviroc (sold as Selzentry in the US and Celsentri in the EU) is a CCR5 receptor antagonist, approved for use in 2007.

Found 4 search result(s) for maraviroc.

Page: HPTN Study 069/ACTG A5305 (2012–2016) (HIV/AIDS Research: Its History & Future Meeting)
... HPTN Study 069 (ACTG A5305) was a Phase II trial of maraviroc (Selzentry, Celsentri) to prevent HIV infection in men who have sex with men ...
Feb 04, 2021
Page: 5.4 Edward Berger — Discovery of HIV Co-receptors (HIV/AIDS Research: Its History & Future Meeting)
... years. We have drugs 00:23:30 that specifically target CCR5. Maraviroc was approved in 2007. These drugs bind within the transmembrane regions. This is a crystal structure of CCR5 ...
Apr 27, 2021
Page: 6.1 Sharon Hillier — Development and Application of Pre-exposure Prophylaxis (PrEP) (HIV/AIDS Research: Its History & Future Meeting)
... CROI this year. 00:05:00 We've seen our first studies of maraviroc alone, and in combination with tenofovir based regimens for PrEP by the HPTN 069 (2012–2016 ...
Apr 27, 2021
Page: 3.5 Daria Hazuda: Discovery and Development of Integrase Inhibitors (HIV/AIDS Research: Its History & Future Meeting)
... two new classes of oral agents to treat HIV infection: the CCR5 antagonists (maraviroc), which I relied on the brilliant work of Ed Berger that you'll hear about ...
Apr 27, 2021

  • No labels